Novo’s Wegovy becomes first GLP-1 drug approved for MASH
The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.
Previous Post
What is Harm Reduction? | National Institute on Drug Abuse
Next Post
Overdose Prevention Strategy
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago